Journal for ImmunoTherapy of Cancer (Nov 2020)

627 The DLL3-targeted half-life extended bispecific T cell engager (HLE BiTE®) immune-oncology therapy AMG 757 has potent antitumor activity in neuroendocrine cancer

  • Keegan Cooke,
  • Jinghui Zhan,
  • Juan Estrada,
  • Marie-Anne Damiette Smit,
  • Aditya Shetty,
  • Jonathan Werner,
  • Fei Lee

DOI
https://doi.org/10.1136/jitc-2020-SITC2020.0627
Journal volume & issue
Vol. 8, no. Suppl 3

Abstract

Read online

No abstracts available.